查詢結果分析
相關文獻
- SGLT-2抑制劑之藥物使用評估
- 糖尿病新藥:SGLT-2抑制劑幫助排糖
- 最新的口服降血糖藥:鈉-葡萄糖共同轉運蛋白-2抑制劑
- Combination of Oral Hypoglycemic Agents and Bedtime Insulin with Ultratard HM in Management of Poorly-controlled NIDDM Subjects
- 口服降血糖藥--磺醯尿素類藥物
- Effects of Insulin therapy on Non-Insulin-Dependent Diabetics with Secondary Oral Hypoglycemic Agent Failure
- Troglitazone--新口服降血糖藥物
- 口服降血糖藥
- 糖尿病控制展新迎姿千禧
- 口服降血糖藥物的選擇
頁籤選單縮合
題 名 | SGLT-2抑制劑之藥物使用評估=Medication-Use Evaluation of Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor |
---|---|
作 者 | 蕭如君; 魏菀葶; 李建瑩; | 書刊名 | 藥學雜誌 |
卷 期 | 34:2=135 2018.06[民107.06] |
頁 次 | 頁124-130 |
分類號 | 418.271 |
關鍵詞 | SGLT-2抑制劑; 口服降血糖藥; 藥物使用評估; Sodium glucose co-transporter 2 inhibitor; SGLT-2i; Oral hypoglycemic agent; OHA; Medication use evaluation; MUE; |
語 文 | 中文(Chinese) |
中文摘要 | 背景:SGLT-2抑制劑 (sodium glucose co-transporter 2 inhibitor, SGLT-2i) 為目前新 機轉的糖尿病用藥,臨床研究顯示其耐受性良好,發生低血糖的機會低,且能降低體 重及血壓,逐漸成為糖尿病治療的新趨勢。SGLT-2i 並不建議使用於中重度腎功能不 全患者,本院部分醫師不合理的處方 SGLT-2i 於此類患者,因此需藉由資訊系統建置 使用標準,以合理使用此新一代用藥來確實達到療效以有效控制疾病,同時減少醫療 資源的浪費。 方法:藥劑科整理 SGLT-2i 在腎功能不全患者的使用標準,經藥事委員會議通過 提請資訊室建置腎功能不全患者使用 SGLT-2i 之比對功能以做設限及提示訊息予醫師 處置建議。評估2016/10/1~2017/3/31系統上線後醫師接受度。 結果:此次 medication-use evaluation, MUE 專案評估結果,2016/1/1~ 2017/9/30在 電腦未建置前,醫師處方 SGLT-2i 於禁忌症 (eGFR < 30 mL/min/1.73 m2) 患者有4名, eGFR 30-45 mL/min/1.73 m2使用 empagliflozin 10 mg/tab 者有10人,eGFR 30-60 mL/ min/1.73 m2使用 dapagliflozin 10 mg/tab 者有24人,總計有38位患者可能並不適合使用 SGLT-2i,顯見本院確實存在一些不合理使用 SGLT-2i 處方。2016/10/1電腦全面建置 設限及提示,嚴格限制開立於禁忌症患者,杜絕此不適當處方發生。系統訊息提示醫 師最近一次患者腎功能及處置建議,提醒醫師處方時再審慎評估。院內2種 SGLT-2i, 2016/10/1~2017/3/31醫師接受更改處方共59人,未接受共15人,接受率為79.7%。追蹤 未接受修改處方,皆屬合理評估使用。 結論:藉由系統全面建置 SGLT-2i 處方於腎功能不全患者之藥物使用標準,確實 獲得顯著成效,有效改善本院合理使用 SGLT-2i 藥物。 |
英文摘要 | Background:SGLT-2 inhibitor (sodium glucose co-transporter 2 inhibitor, SGLT-2i) is an oral hypoglycemic agent whose mechanism is currently well explored. Previous clinical studies suggested SGLT-2 has a good tolerability profile ,the events of hypoglycemia is low in clinic and it also can reduce weight and blood pressure. It has become the trend of treating diabetes in recent years. SGLT-2i should not be suggest in the patients with moderate-tosevere renal dysfunction but some physicians in our hospital prescribed SGLT-2i to this kind of patient incorrectly. So, we need to create a standard with the computer system for controlling disease effectively by using this medicine rationally and reduced the waste of medical resources at the same time. Method: In our department of pharmacy, we organized the standard of using SGLT- 2i in the patient of renal impairment,pharmaceuticals committee adopted through submit to department of information construction renal impairment patient using SGLT-2i, in order to limit and sent prompting information to the doctor performing suggestion. And that, we assess the acceptance rate in doctors after creating the standard of system from Oct. 1, 2016 till Mar. 31, 2017. Result: The result of this medication-use evaluation, MUE project showed that before the computer not construction, doctor prescribed SGLT-2i at contraindications (eGFR < 30 mL/ min /1.73 m2) during 2016/1/1 to 2016/9/30 to 4 people, eGFR 30-45 mL/min/1.73 m2 used empagliflozin 10 mg/tab to 10 people, eGFR 30-60 mL/min/1.73 m2 used dapagliflozin 10 mg/tab to 24 people, it may be unsuitable to use SGLT-2i up to 38 patients totally,obviously there were unreasonable using SGLT-2i prescriptions in our hospital. The overall construction of the computer limited and prompted function was since 2016/10/01. It restrains doctor’s prescriptions at contraindications strictly, put an end to danger of medication. Systematic information immediately notifies the doctor about patient's renal function, performs suggestion and reminds doctor prudent assessment while prescribing. Two kinds of SGLT-2i were used in our hospital, totally 59 persons for doctor’s accepting the prescription changing during 2016/10/1 to 2017/3/31, up to 15 persons have not accepted, the accepting rate is 79.7%. Tracing those prescriptions have not been accepted by doctors all attributed to be used rationally. Conclusion: To create the standard of using SGLT-2i in the patient of renal impairment with the computer system really gains the effectiveness obviously and improves it’s rational using in our hospital. |
本系統中英文摘要資訊取自各篇刊載內容。